CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast

[1] Oberman HA(1987)Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients Am J Surg Pathol 11 918-929

[2] Rakha EA(2015)Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study Br J Cancer 112 283-289

[3] Tan PH(2015)Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy Curr Oncol Rep 17 431-194

[4] Varga Z(2013)Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer J Surg Oncol 107 188-99

[5] Tse GM(2013)Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators World J Surg Oncol 11 129-185

[6] Shaaban AM(2007)CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer Cells Tissues Organs 185 95-4828

[7] Climent F(2004)WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer Neoplasia 6 179-R1089

[8] van Deurzen CH(2012)CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer Cancer Res 72 4818-904

[9] Purnell D(2005)Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells Breast Cancer Res 7 R1080-3180

[10] Dodwell D(2008)Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1 Am J Pathol 172 893-2285

[1] Oberman HA(1987)Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients Am J Surg Pathol 11 918-929

[2] Rakha EA(2015)Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study Br J Cancer 112 283-289

[3] Tan PH(2015)Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy Curr Oncol Rep 17 431-194

[4] Varga Z(2013)Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer J Surg Oncol 107 188-99

[5] Tse GM(2013)Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators World J Surg Oncol 11 129-185

[6] Shaaban AM(2007)CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer Cells Tissues Organs 185 95-4828

[7] Climent F(2004)WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer Neoplasia 6 179-R1089

[8] van Deurzen CH(2012)CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer Cancer Res 72 4818-904

[9] Purnell D(2005)Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells Breast Cancer Res 7 R1080-3180

[10] Dodwell D(2008)Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1 Am J Pathol 172 893-2285